Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Kenvue

Johnson & Johnson Risks UK Lawsuit Over Talc Cancer Claim

UK claimants announced Wednesday legal action against US pharmaceutical and cosmetics giant Johnson & Johnson, alleging that women diagnosed with cancers were exposed to asbestos in the company's talcum powder.

International Business Times

Stocks With Rising Relative Strength: Kenvue

Kenvue shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Kenvue Shows Rising Price Performance With Jump To 82 RS Rating

Kenvue shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises

Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.

Investors Business Daily

Nvidia Among Five Best S&P 500 Stocks Today

Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia stock was close behind, breaking out to a record high.

Investors Business Daily

Stocks trading lower: Boeing, Kenvue, ASML, and more are big movers

Here are the stocks making the biggest market moves midday.

The Street

What’s Behind the Rally in Kenvue Stock Today?

Starboard Value is reportedly eyeing changes at KVUE as the stock underperforms the broader market.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Starboard Value Buys Into Dow Jones Spinoff; ELF Beauty Rallies

Elf Beauty appeared to rally along with KVUE on Monday.

Investors Business Daily

Kenvue Stock: Is KVUE Outperforming the Consumer Defensive Sector?

Kenvue has recently outperformed the consumer defensive sector, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

3 Defensive Dividend Stocks to Protect Against Pre-Election Volatility

As the U.S. presidential election nears, here are three defensive dividend-paying stocks to help shield your portfolio from pre-election volatility.

Barchart

This Dividend Aristocrat Just Had Its Best Day Ever After Earnings

This dividend aristocrat crushed Q2 earnings and issued strong guidance, and still has some fuel left in the tank for more growth.

Barchart

3 Dividend Stocks Set to Triple Your Income in the Next Decade

Looking for a lifetime of increasing dividends? Here's 3 stocks that could fit the bill.

Barchart

This Morning’s Dr Zoe Williams: Nobody should be smoking at home where there’s a child or pregnant mother

Quitting smoking can be extremely difficult, but there are lots of treatments options out there to help.

The Independent UK

What to Expect From Kenvue's Q2 2024 Earnings Report

Kenvue is all set to announce its second-quarter results this month, and analysts forecast a single-digit decline in the company’s bottom-line figure.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Kenvue Stock Underperforming the Dow?

While Kenvue's shares have notably lagged behind the Dow Jones in the past year, analysts hold a moderately bullish outlook on the stock.

Barchart

3 High-Yield Dividend Stocks to Build a Passive Income Stream

When the market pulls back, it's an opportunity to invest in high-yield dividend stocks like Kenvue, Enterprise Products Partners, and Verizon, which offer attractive yields and growth potential.

Barchart

Kenvue Stock: Is Wall Street Bullish or Bearish?

Despite Kenvue lagging behind the broader market, Wall Street analysts remain optimistic about the stock’s prospects.

The Independent UK

Stock market today: Asian shares gain after Wall Street ticks higher amid rate-cut hopes

Asian shares have mostly advanced after Wall Street ticked higher amid hopes that Japan's moves to keep interest rates easy for investors could augur similar trends in the rest of the world

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Johnson & Johnson earnings top forecasts on new cancer drug boost

Johnson & Johnson's newly-structured business, which no longer includes a consumer healthcare unit, is seeing solid demand for its new cancer-focused treatments Carvykti and Tecvayli.

StockNews.com

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

Fortune

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Fortune

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Barchart

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

The Independent UK

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

Investors Business Daily

Stock Market Trims Gains, Dow Hangs By A Thread; Tesla Leads S&P 500

Twinkies maker Hostess Brands soared on news the snack company will be acquired by J.M. Smucker.

1 2

People

Janet Yellen

1,181 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.